PharVision Advisers’s RTX Corp RTX Stock Holding History

PharVision Advisers’s Portfolio RTX Stock Details RTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,886	Closed	-$218K	–	482
2024 Q4	$218K	Buy	+1,886	New	+$228K	0.18%	266

Other funds holding RTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PharVision Advisers's RTX Position: Q1 2025 in Review

PharVision Advisers sold out of RTX Corp (RTX) in Q1 2025, closing a stake of 1,886 shares — an estimated $218K sold.

PharVision Advisers first reported a position in RTX in Q4 2024 and held it in 1 quarter. The position peaked at $218K in Q4 2024. 2,914 funds tracked by Wall St. Rank hold RTX as of Q1 2025.

PharVision Advisers reported no remaining RTX Corp position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 1,886 RTX Corp shares in Q1 2025, an estimated $218K.
PharVision Advisers first reported a position in RTX Corp in Q4 2024 and held it in 1 quarter.
PharVision Advisers's RTX Corp position peaked at $218K in Q4 2024.
2,914 funds tracked by Wall St. Rank held RTX Corp as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.